Sofosbuvir and daclatasvir therapy in patients with hepatitis C‐related advanced decompensated liver disease (MELD ≥ 15)

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|3|401-411

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.3, 2018-02, pp. : 401-411

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C‐related cirrhosis, genotype 4

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 674-679

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient with decompensated hepatitis C virus–related cirrhosis delisted for liver transplantation after successful sofosbuvir‐based treatment

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 3, 2015-03 ,pp. : 408-409

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lamivudine Therapy for Decompensated Liver Cirrhosis Related to Hepatitis B Virus Infection

By  

Intervirology, Vol. 46, Iss. 6, 2003-12 ,pp. : 388-393

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C–Infected Patients With Compensated and Decompensated Cirrhosis

By  

HEPATOLOGY, Vol. 62, Iss. 3, 2015-09 ,pp. : 715-725

John Wiley & Sons Inc

Access to resources Recommend Favorite

Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real‐world results from 18 378 patients in Egypt

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 3, 2018-02 ,pp. : 421-431

John Wiley & Sons Inc

Access to resources Recommend Favorite